Ascend Wellness Holdings (AAWH) Amortization of Deferred Charges (2020 - 2026)
Ascend Wellness Holdings' (AAWH) quarterly Amortization of Deferred Charges came in at $765000.0 in Q1 2026, up 8.05% year-on-year from $708000.0 in Q1 2025, and up 49.41% quarter-over-quarter from $512000.0 in Q4 2025.
Ascend Wellness Holdings (AAWH) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $765000.0 for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 8.05% year-over-year to $765000.0 in Q1 2026; TTM through Mar 2026 was $2.1 million, a 4.5% decrease from a year earlier, with the FY2025 full-year figure at $2.1 million, up 5.09% from the prior year.
- Amortization of Deferred Charges rose to $765000.0 in Q1 2026 per AAWH's latest filing, from $512000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $765000.0 in Q1 2026 and bottomed at $122000.0 in Q4 2022.
- The 5-year median for Amortization of Deferred Charges is $451000.0 (2024), against an average of $410823.5.
- Across the five-year window, Amortization of Deferred Charges slumped 62.46% in 2022 and surged 127.43% in 2024, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $122000.0 in 2022, then soared by 85.25% to $226000.0 in 2023, then jumped by 127.43% to $514000.0 in 2024, then retreated by 0.39% to $512000.0 in 2025, then surged by 49.41% to $765000.0 in 2026.
- Per Business Quant, the three latest AAWH Amortization of Deferred Charges figures stand at $765000.0 (Q1 2026), $512000.0 (Q4 2025), and $359000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Ascend Wellness Holdings | 78.95 Mn | 18.03 Mn | 44.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 765,000.00 |
| Mar 31, 2026 | 765,000.00 |
| Dec 31, 2025 | 512,000.00 |
| Dec 31, 2025 | 512,000.00 |
| Sep 30, 2025 | 359,000.00 |
| Sep 30, 2025 | 359,000.00 |
| Jun 30, 2025 | 486,000.00 |
| Jun 30, 2025 | 486,000.00 |
| Mar 31, 2025 | 708,000.00 |
| Mar 31, 2025 | 708,000.00 |
| Dec 31, 2024 | 514,000.00 |
| Dec 31, 2024 | 514,000.00 |
| Sep 30, 2024 | 486,000.00 |
| Sep 30, 2024 | 486,000.00 |
| Jun 30, 2024 | 514,000.00 |
| Jun 30, 2024 | 514,000.00 |
| Mar 31, 2024 | 451,000.00 |
| Mar 31, 2024 | 451,000.00 |
| Dec 31, 2023 | 226,000.00 |
| Dec 31, 2023 | 226,000.00 |